Search through
Lamotrigine is a broad-spectrum antiepileptic drug (AED) that belongs to the phenyltriazine class. It acts by inhibiting voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing excitatory neurotransmitter release, particularly glutamate. This mechanism provides efficacy across a variety of seizure types and makes it a valuable option in bipolar disorder maintenance therapy. It is administered orally and is known for its favorable bioavailability, metabolic stability, and low risk of weight gain or sedation. High-purity Lamotrigine, phenyltriazine anticonvulsant.
Lamotrigine is a broad-spectrum antiepileptic drug (AED) that belongs to the phenyltriazine class. It acts by inhibiting voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing excitatory neurotransmitter release, particularly glutamate. This mechanism provides efficacy across a variety of seizure types and makes it a valuable option in bipolar disorder maintenance therapy. It is administered orally and is known for its favorable bioavailability, metabolic stability, and low risk of weight gain or sedation. High-purity Lamotrigine, phenyltriazine anticonvulsant.
Chemical Properties & Specifications
Acute oral toxicity (Category 3), Irritant (skin/eye)
Used in the manufacture of oral dosage forms to treat focal seizures, generalized tonic-clonic seizures, and Lennox–Gastaut syndrome. Also utilized as a long-term mood stabilizer in bipolar I disorder.
Effective across multiple seizure types and bipolar disorder
≥98% absorption with minimal first-pass metabolism
24–35 hours, supporting once-daily dosing in many cases
Not a CYP inducer or inhibitor
Resistant to hydrolysis and oxidation under standard conditions
Store at 2–8 °C in tightly sealed, light-resistant containers
Stable at 2–8 °C; shelf life ≥ 2 years under recommended condition
Available in HDPE drums or fiberboard containers with double PE liners; sampling in 100 g – 1 kg aluminum bottles
Non-hazardous; not regulated under IMDG/IATA
It inhibits voltage-gated sodium channels, reducing presynaptic glutamate and aspartate release, thus stabilizing neuronal activity.
Lamotrigine has a bioavailability of ~98%, a half-life of 24–35 hours, and protein binding of approximately 55%.
Not scheduled.
Compliant with Q3A (impurities), Q6A (specifications)
Yes, especially in Lennox–Gastaut syndrome and partial seizures, with dose adjustments based on age and weight.
Typically supplied as an API for use in immediate and extended-release tablets; dispersible forms are also common.
Avoid skin contact and inhalation. Use PPE during compounding. Risk of skin rash necessitates safe handling procedures.
FDA: Approved and listed on the WHO Essential Medicines List.
EMA, MHRA, Health Canada: Globally registered for epilepsy and bipolar disorder.
